Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.metabol.2020.154413 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Resmetirom for metabolic dysfunction-associated steatohepatitis: targeting hepatic and cardiovascular disease.
Hepatobiliary Surg Nutr
December 2024
Department of Hepatology and Gastroenterology, Campus Charité Mitte and Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Addressing the alarming link between nonalcoholic fatty liver disease and cardiovascular mortality in men.
World J Cardiol
September 2024
Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung 404328, Taiwan.
This editorial discusses the key findings presented in Batta and Hatwal's recent paper titled "Excess cardiovascular mortality in men with non-alcoholic fatty liver disease: A cause for concern!", which was published in the . Their original article highlights a notable correlation between nonalcoholic fatty liver disease (NAFLD) and increased cardiovascular mortality risk in men. The present commentary explores the implications of their findings, discussing potential mechanisms, risk factors, and the urgent need for integrated clinical approaches to mitigate the dual burden of these diseases.
View Article and Find Full Text PDFLessons from PROMINENT and prospects for pemafibrate.
Cardiovasc Diabetol
July 2024
Department of Medicine - DIMED, University of Padua, Padua, Italy.
The neutral result of the PROMINENT trial has led to questions about the future for pemafibrate. This commentary discusses possible reasons for the lack of benefit observed in the trial. There were, however, indicators suggesting therapeutic potential in microvascular ischaemic complications associated with peripheral artery disease, with subsequent analysis showing reduction in the incidence of lower extremity ischaemic ulceration or gangrene.
View Article and Find Full Text PDFRacial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease outcomes: A call for culturally sensitive interventions: Editorial on "Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study".
Clin Mol Hepatol
October 2024
Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on "Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis".
Clin Mol Hepatol
October 2024
Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!